Quotes 5-day view Real-time Euronext Paris
01/11/2021
01/12/2021
01/13/2021
01/14/2021
01/15/2021
Date
116.2(c)
114.7(c)
118.1(c)
116.3(c)
117.5(c)
Last
89 701
101 447
145 720
80 092
92 524
Volume
-0.51% -1.29% +2.96% -1.52% +1.03% Change
Sales 2020
3 135 M 3 786 M 3 786 M
Net income 2020
403 M 487 M 487 M
Net Debt 2020
89,8 M 108 M 108 M
P/E ratio 2020
34,7x
Yield 2020
0,39%
Sales 2021
3 303 M 3 988 M 3 988 M
Net income 2021
405 M 489 M 489 M
Net cash position 2021
145 M 175 M 175 M
P/E ratio 2021
34,4x
Yield 2021
0,43%
Capitalization
13 902 M 16 808 M 16 787 M
EV / Sales 2020
4,46x
EV / Sales 2021
4,17x
Nbr of Employees
12 000
Free-Float
31,2%
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (82.5%): in industry, microbiological testing of samples from...
Notations Surperformance© of bioMérieux
Trading Rating : Investor Rating :
All news about BIOMÉRIEUX
News in other languages on BIOMÉRIEUX
Analyst Recommendations on BIOMÉRIEUX
BIOMÉRIEUX - 2020
A medium term support level to take advantage of
BUY
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends BIOMÉRIEUX
Short Term Mid-Term Long Term Trends Neutral Bearish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
HOLD
Number of Analysts
14
Average target price
124,48 €
Last Close Price
117,50 €
Spread / Highest target
31,1%
Spread / Average Target
5,94%
Spread / Lowest Target
-43,0%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
